A Phase 2 interventional study of Ravulizumab in Preeclampsia, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
916 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
This study's planned enrollment of 14 is below the median of 110 across 480 interventional studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive an single-dose infusion of Ravulizumab.
Drug: Ravulizumab
Intravenous infusion 100 mg/ml
Also known as: Ultomiris
Alternative Complement Pathway Biomarkers at time of delivery
Concentration in serum of biomarkers: sMAC, Bb, and C5 at time of delivery
Time frame: Baseline
Pregnancy duration
Length of pregnancy measured in number of weeks.
Time frame: Approximately 40 weeks
Clinical biomarkers of severe features of preeclampsia and HELLP syndrome
Concentration of clinical biomarkers in serum: creatinine, AST, ALT, LDH and platelets
Time frame: 72 hours after Ravulizumab infusion
Hospitalization length in the postpartum period
Length of hospital stay measured in number of days in hospital stay (peripartum period)
Time frame: Approximately 3-5 days, it may vary
Meningococcal infection after use of ravulizumab
Number of participants to present a meningococcal infection after use of Ravulizumab
Time frame: 72 hours up to 3 weeks after Ravulizumab infusion
Plan to share: No
Start is estimated for Apr 2027; primary completion for Dec 2028, 20 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Apr 2027, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab